Syros Pharmaceuticals, Inc. - SYRS STOCK NEWS

Welcome to our dedicated page for Syros Pharmaceuticals news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals stock.

Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.

At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.

While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.

Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.

Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.

03/20/2024 07:00 AM

News

Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024

Rhea-AI Summary

Syros Pharmaceuticals (SYRS) to report Q4 and full year 2023 financial results and host conference call on March 27, 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.61%

Tags

02/27/2024 07:00 AM

News

Syros to Participate in TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary

Syros Pharmaceuticals CEO to Participate in Panel Discussion at TD Cowen 44th Annual Health Care Conference

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2%

Tags

01/08/2024 07:00 AM

News

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene

Rhea-AI Summary

Syros Pharmaceuticals (SYRS) is on track to complete enrollment of 190 patients for primary analysis in the SELECT-MDS-1 Phase 3 trial in 1Q 2024. Pivotal CR data is expected by mid-4Q 2024. Additional data from the SELECT-AML-1 Phase 2 trial is also expected in 2024, with initial data demonstrating a 100% CR/CRi rate and a strengthened balance sheet with gross proceeds of approximately $45.0 million from recent equity financing, extending cash runway into 2Q 2025.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.58%

Tags

12/19/2023 07:27 AM

News

Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants

Rhea-AI Summary

Syros Pharmaceuticals (SYRS) announces pricing of underwritten offering of common stock and pre-funded warrants, expecting to raise approximately $45.0 million.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

30.93%

Tags

12/06/2023 07:00 AM

News

Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ: SYRS) announced strong initial data from its SELECT-AML-1 Phase 2 trial evaluating tamibarotene, venetoclax, and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression. The primary endpoint of complete response rate (CR)/complete response with incomplete hematologic recovery (CRi) was 100% among patients treated with the triplet regimen compared to 70% in patients treated with venetoclax and azacitidine alone. Additional data is expected in 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

42.55%

Tags

11/21/2023 07:30 AM

News

Syros to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Syros Pharmaceuticals (SYRS) management will participate in fireside chats at the Piper Sandler 35th Annual Healthcare Conference and the JMP Securities Hematology and Oncology Summit. The webcasts and archived recordings will be available on the Syros website.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.05%

Tags

11/14/2023 07:30 AM

News

Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ: SYRS) reported financial results and provided a corporate update. The company is on track to report initial data from the SELECT-AML-1 trial in early December 2023 and pivotal CR data from SELECT-MDS-1 by mid-4Q 2024. Founding CEO, Nancy Simonian, M.D., will retire, and Conley Chee will succeed as CEO. The company is focused on advancing tamibarotene for the frontline treatment of hematologic malignancies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.12%

Tags

11/07/2023 07:30 AM

News

Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) will host a conference call and webcast on November 14, 2023, to report its third quarter 2023 financial results and provide a corporate update.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.36%

Tags

10/02/2023 08:45 AM

News

Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company

Rhea-AI Summary

Syros Pharmaceuticals announces strategic realignment to prioritize development of tamibarotene for HR-MDS and AML. Workforce reduction of approximately 35% implemented. Conley Chee appointed as CEO, effective December 2, 2023. Nancy Simonian to retire as CEO and remain on the Board of Directors. Tamibarotene has potential to set new standard of care for RARA overexpression patients. Company will stop further investment in SY-2101 development. Eric Olson, Chief Scientific Officer, to depart effective October 16, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-18.73%

Tags

09/07/2023 04:30 PM

News

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Syros Pharmaceuticals grants 20,650 restricted stock units (RSUs) to new employees as inducement to employment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.52%

Tags

FAQ

What is the current stock price of Syros Pharmaceuticals (SYRS)?

The current stock price of Syros Pharmaceuticals (SYRS) is $0.292439 as of November 22, 2024.

What is the market cap of Syros Pharmaceuticals (SYRS)?

The market cap of Syros Pharmaceuticals (SYRS) is approximately 7.8M.

What does Syros Pharmaceuticals specialize in?

Syros Pharmaceuticals specializes in mapping gene regulatory circuits and modulating factors that control gene expression to treat diseases.

What is unique about Syros Pharmaceuticals' approach?

Syros utilizes a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to decode gene regulation for therapeutic development.

In which therapeutic areas has Syros Pharmaceuticals shown success?

Syros has demonstrated success primarily in oncology, addressing unmet medical needs in hematologic malignancies.

What recent achievements has Syros Pharmaceuticals made?

Syros has continued to advance its clinical pipeline and establish strategic partnerships to drive innovation in gene control research.

What is the financial condition of Syros Pharmaceuticals?

Syros is well-funded and strategically positioned to continue its extensive research and development efforts in precision medicine.

What is the proprietary platform of Syros Pharmaceuticals?

It is a combination of assay technologies, bioinformatics, and biological insights developed to understand and modulate gene regulation.

How does Syros Pharmaceuticals impact patient treatment?

Syros develops new standards of care for frontline treatment, particularly for patients with hematologic malignancies, aiming to improve patient outcomes.

Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?

Syros is making its mark by leveraging its gene control research to develop innovative therapies, especially in oncology.

Who are the key contributors to Syros Pharmaceuticals' proprietary platform?

The platform has been developed by the experienced senior leadership team at Syros, integrating their expertise in disease biology and genomics.

What is the mission of Syros Pharmaceuticals?

The mission of Syros Pharmaceuticals is to transform the treatment of diseases by harnessing the power of gene control research to develop innovative therapies.